Teijin Limited Revises FY2026 Forecast — Operating Profit Swings to Loss of Up to JPY 85bn on Impairment
Teijin Limited (TSE:3401) has revised its earnings forecast for the fiscal year ending March 2026, with a significant downward adjustment to operating profit.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 860.0bn | JPY 860.0bn | 0 |
| Business Profit (Jigyō Rieki) | JPY 25.0bn | JPY 25.0bn | 0 |
| Operating Profit | JPY 5.0bn | △75.0bn～△85.0bn | △80.0bn～△90.0bn |
| Net Profit | JPY △10.0bn | △85.0bn～△95.0bn | △95.0bn～△105.0bn |
| EPS | JPY △51.85 | △440.76～△492.62 | △388.87～△440.77 |
The revision follows a shift in the expected completion date of a stock sale from April 2026 to the fiscal year ending March 2027, which could impact consolidated results. Additionally, the company is reassessing its pharmaceutical business strategy, focusing on rare disease and orphan drug areas, leading to potential impairment charges related to its stake in Teijin Pharma. A reassessment of deferred tax assets also contributed to the adjustment.
The downward revision reflects management’s concerns over the potential negative impact on future performance due to these strategic and accounting changes. Investors should closely monitor subsequent financial reports and any further adjustments to asset valuations.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.